2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Omics Technologies, Pathology, Serologic Tests, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Immunology, Immunodeficiency, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

2225 Treatment patterns across lines of therapy among patients with newly diagnosed multiple myeloma in the United States

Ariel F. Grajales-Cruz, MD, Craig Cole2, Noa Biran, MD3, Ajay K Nooka, MD, MPH4, Yunji Hwang5, Ashley Holub6, Neal Sule, MD, MSc7, Omar Ladhani8, Madeline Richey9, Michael Chiu10, Amy E. Pierre, MSN, ANP-BC11, Jonathan Bryan12, Kui Huang13, Natasha Edwin, MD14
1 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States
2 Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States, Division of Hematology and Oncology, Michigan State University, Lansing, MI, United States
3 Hackensack Meridian School of Medicine, Nutley, NJ, United States, John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ, United States
4 Emory Winship Cancer Institute, Atlanta, GA, United States
5 GSK, Upper Providence, PA, United States
6 GSK, Upper Providence, PA, United States
7 GSK, Upper Providence, PA, United States
8 GSK, Upper Providence, PA, United States
9 Flatiron Health, New York, NY, United States
10 Flatiron Health, New York, NY, United States
11 Flatiron Health, New York, NY, United States
12 Flatiron Health, New York, NY, United States
13 GSK, Upper Providence, PA, United States
14 Providence Cancer Center Oncology and Hematology Care Clinic, Portland, OR, United States

Introduction: The therapeutic landscape for multiple myeloma (MM) is evolving rapidly; however, the extent to which patients subsequently receive T-cell-redirecting therapies is not well characterized. This study evaluated evolving real-world treatment patterns by line of therapy (LoT), temporal trends, and patient attrition rates between subsequent LoTs among newly diagnosed and treated patients with MM in the United States.

Methods: This retrospective, longitudinal cohort study utilized the US-based, electronic health record-derived, deidentified Flatiron Health Research Database to analyze adult patients (≥18 years old) with MM who initiated first-line (1L) treatment between 2020 and 2025. Regimens were grouped hierarchically as chimeric antigen receptor T-cell (CAR-T) therapy, bispecific antibody (BsAb), anti-CD38 monoclonal antibody (aCD38), and others. Descriptive analyses were performed to characterize regimen distribution and attrition across LoTs.

Results: Among 7364 patients initiating 1L therapy, median age at index was 70 years (interquartile range [IQR] interval: 62–77); 54.8% were male, 56.7% were white, and 21.1% received stem cell transplant (SCT) in 1L. During the study period, aCD38-containing regimens were administered in 45.1% of patients in 1L, but the bortezomib, lenalidomide, and dexamethasone (VRd) regimen was the most common regimen overall (30.0%), including non-SCT recipients (29.0%), while daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) was the predominant regimen among SCT recipients (33.8%). From second-line (2L) onward, aCD38-containing regimens (received in any combination without CAR-T or BsAb) were highly prevalent, accounting for 65.0%, 51.7%, 39.3%, and 27.8% of treatments in 2L, third-line (3L), fourth-line (4L), and fifth-line (5L), respectively. Regarding trends over time, the proportion of aCD38 use in 1L and 2L increased from 2020 to 2025, reaching 93.8% among SCT recipients (1L), 75.0% among non-SCT recipients (1L), and 73.1% (2L) in 2025. Notably, uptake of CAR-T and BsAb therapies remained limited even in later lines (up to 31.6% in 5L); furthermore, patient attrition was substantial, with 54.5–56.8% of patients not advancing to a subsequent line across all LoTs.

Conclusions: In this contemporary US real-world longitudinal cohort study, aCD38-containing regimens rapidly expanded in 1L, with many patients being retreated with aCD38 in subsequent lines. Further, the limited uptake of novel therapeutic modalities such as T-cell-redirecting therapies until later lines is consequential, given the substantial attrition observed with each successive LoT. Collectively, these findings define a population-level sequencing that may inform clinical trial design, external-context interpretation, and future research on accessible novel therapies, as well as practical administration requirements to improve care beyond aCD38 retreatment.

Ariel F. Grajales-Cruz, MD: Regeneron - Honoraria; Pfizer - Honoraria; Sanofi - Honoraria; Amgen - Honoraria; BMS - Honoraria; GSK - Honoraria; Janssen - Honoraria; Janssen - Research Funding; Cellectar - Consultancy (Includes expert testimony)